Cargando…

Vaccine Strategies

The new technologies of genomics, proteomics, and molecular immunology have led to an impressive increase in our knowledge of all aspects of virology, providing insights that can guide new vaccine concepts. When developing a new vaccine, the choice of approach is made very much on a case-by-case bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusters, I., Almond, J.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150003/
http://dx.doi.org/10.1016/B978-012374410-4.00597-5
_version_ 1783520932442144768
author Kusters, I.
Almond, J.W.
author_facet Kusters, I.
Almond, J.W.
author_sort Kusters, I.
collection PubMed
description The new technologies of genomics, proteomics, and molecular immunology have led to an impressive increase in our knowledge of all aspects of virology, providing insights that can guide new vaccine concepts. When developing a new vaccine, the choice of approach is made very much on a case-by-case basis, and for a given virus is driven by knowledge its pathogenesis, serotype diversity, antigenic variation, immune evasion mechanisms, latency and route of transmission. High importance is given to what type of immunity arises as a result of natural infection and whether the pathogen can cause persistent and/or repeated infections in a single host. This article discusses the medical need for new human viral vaccines and focuses on the strategies available for their development and some of the challenges posed by the more difficult targets.
format Online
Article
Text
id pubmed-7150003
institution National Center for Biotechnology Information
language English
publishDate 2008
record_format MEDLINE/PubMed
spelling pubmed-71500032020-04-13 Vaccine Strategies Kusters, I. Almond, J.W. Encyclopedia of Virology Article The new technologies of genomics, proteomics, and molecular immunology have led to an impressive increase in our knowledge of all aspects of virology, providing insights that can guide new vaccine concepts. When developing a new vaccine, the choice of approach is made very much on a case-by-case basis, and for a given virus is driven by knowledge its pathogenesis, serotype diversity, antigenic variation, immune evasion mechanisms, latency and route of transmission. High importance is given to what type of immunity arises as a result of natural infection and whether the pathogen can cause persistent and/or repeated infections in a single host. This article discusses the medical need for new human viral vaccines and focuses on the strategies available for their development and some of the challenges posed by the more difficult targets. 2008 2008-07-30 /pmc/articles/PMC7150003/ http://dx.doi.org/10.1016/B978-012374410-4.00597-5 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kusters, I.
Almond, J.W.
Vaccine Strategies
title Vaccine Strategies
title_full Vaccine Strategies
title_fullStr Vaccine Strategies
title_full_unstemmed Vaccine Strategies
title_short Vaccine Strategies
title_sort vaccine strategies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150003/
http://dx.doi.org/10.1016/B978-012374410-4.00597-5
work_keys_str_mv AT kustersi vaccinestrategies
AT almondjw vaccinestrategies